Study · Randomized controlled trial · n = 105 · 2012

8 results

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.

Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L and 6 more

Show all authors

Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrøm T

European heart journal14 Sept 2011Cited by 421 (Europe PMC)

PMID21920963DOI10.1093/eurheartj/ehr309PepBankPUB-21920963

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In STEMI patients undergoing pPCI, exenatide increased myocardial salvage index versus placebo.
In plain wordsIn patients with STEMI undergoing pPCI, exenatide increased the heart muscle salvage index compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseMyocardial salvage index
Study
n = 105
Comparator
Placebo (saline)
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 min before intervention and maintained for 6 h after the procedureAs given in this study (human).
Measurements
Salvage index
0.71 index
exenatide
Salvage index
0.62 index
placebo
Source sentences
Summary
In 105 patients evaluated with CMR, a significantly larger salvage index was found in the exenatide group than in the placebo group (0.71 ± 0.13 vs. 0.62 ± 0.16; P= 0.003).
3 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was salvage index calculated from myocardial area at risk (AAR), measured in the acute phase, and final infarct size measured 90 ± 21 days after pPCI by cardiac magnetic resonance (CMR).
Summary · context
A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously.
Summary · context
Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure.
Report a problemFND-2192096301
02HumanRandomized controlled trialEfficacy outcome
In STEMI patients undergoing pPCI, exenatide reduced infarct size relative to area at risk versus placebo.
In plain wordsIn patients with STEMI undergoing pPCI, exenatide reduced infarct size relative to the area at risk compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInfarct size relative to area at risk
Study
n = 105
Comparator
Placebo (saline)
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 min before intervention and maintained for 6 h after the procedureAs given in this study (human).
Measurements
Infarct size/AAR
0.3 ratio
exenatide
Infarct size/AAR
0.39 ratio
placebo
Source sentences
Summary
Infarct size in relation to AAR was also smaller in the exenatide group (0.30 ± 0.15 vs. 0.39 ± 0.15; P= 0.003).
3 context sentences(design, population, supporting numbers)
Summary · context
In 105 patients evaluated with CMR, a significantly larger salvage index was found in the exenatide group than in the placebo group (0.71 ± 0.13 vs. 0.62 ± 0.16; P= 0.003).
Summary · context
A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously.
Summary · context
Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure.
Report a problemFND-2192096302
03HumanRandomized controlled trialEfficacy outcome
In STEMI patients, covariance analysis showed lower infarct size relative to area at risk with exenatide than placebo.
In plain wordsIn patients with STEMI, adjusted analysis showed lower infarct size relative to the area at risk with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInfarct size adjusted for area at risk
Study
n = 105
Comparator
Placebo (saline)
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 min before intervention and maintained for 6 h after the procedureAs given in this study (human).
Source sentences
Summary
In a regression analysis, there was a significant correlation between the infarct size and the AAR for both treatment groups and an analysis of covariance showed that datapoints in the exenatide group lay significantly lower than for the placebo group (P= 0.011).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously.
Summary · context
Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure.
Report a problemFND-2192096303
04HumanRandomized controlled trialEfficacy outcome
In STEMI patients, absolute infarct size tended to be smaller with exenatide than placebo, without statistical significance.
In plain wordsIn patients with STEMI, absolute infarct size tended to be smaller with exenatide than placebo, but the difference was not significant.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAbsolute infarct size
Study
n = 105
Comparator
Placebo (saline)
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 min before intervention and maintained for 6 h after the procedureAs given in this study (human).
Measurements
Absolute infarct size
13 g
exenatide
Absolute infarct size
17 g
placebo
Source sentences
Summary
There was a trend towards smaller absolute infarct size in the exenatide group (13 ± 9 vs. 17 ± 14 g; P= 0.11).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously.
Summary · context
Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure.
Report a problemFND-2192096304
05HumanRandomized controlled trialEfficacy outcome
In STEMI patients undergoing pPCI, analysis of covariance showed infarct size relative to area at risk lay significantly lower with exenatide than with placebo (P = 0.011).
In plain wordsIn patients with STEMI, infarct size for a given area at risk was lower with exenatide than with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInfarct size adjusted for area at risk (analysis of covariance)
Study
n = 105
Comparator
Placebo (saline)
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 min before intervention and maintained for 6 h after the procedureAs given in this study (human).
Source sentences
Summary
In a regression analysis, there was a significant correlation between the infarct size and the AAR for both treatment groups and an analysis of covariance showed that datapoints in the exenatide group lay significantly lower than for the placebo group (P= 0.011).
2 context sentences(design, population, supporting numbers)
Summary · context
In 105 patients evaluated with CMR, a significantly larger salvage index was found in the exenatide group than in the placebo group (0.71 ± 0.13 vs. 0.62 ± 0.16; P= 0.003).
Summary · context
A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously.
Report a problemFND-2192096308
06HumanRandomized controlled trialEfficacy outcome
In STEMI patients, left ventricular function did not differ between exenatide and placebo.
In plain wordsIn patients with STEMI, left ventricular function did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLeft ventricular function
Study
n: not reported in source
Comparator
Placebo (saline)
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 min before intervention and maintained for 6 h after the procedureAs given in this study (human).
Source sentences
Summary
No difference was observed in left ventricular function or 30-day clinical events.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously.
Summary · context
Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure.
Report a problemFND-2192096305
07HumanRandomized controlled trialEfficacy outcome
In STEMI patients, clinical events at 30 days did not differ between exenatide and placebo.
In plain wordsIn patients with STEMI, clinical events at 30 days did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant change30-day clinical events
Study
n: not reported in source
Comparator
Placebo (saline)
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · intravenous · 15 min before intervention and maintained for 6 h after the procedureAs given in this study (human).
Source sentences
Summary
No difference was observed in left ventricular function or 30-day clinical events.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously.
Summary · context
Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure.
Report a problemFND-2192096306
08HumanRandomized controlled trialSafety outcome
In STEMI patients undergoing pPCI, no adverse effects of exenatide were observed.
In plain wordsIn patients with STEMI undergoing pPCI, researchers observed no adverse effects of exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableAdverse effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intravenous · 15 min before intervention and maintained for 6 h after the procedureAs given in this study (human).
Source sentences
Summary
No adverse effects of exenatide were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously.
Summary · context
Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure.
Report a problemFND-2192096307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials6

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

6 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial page ClinicalTrials.govUpdated 12 Oct 2016

CompletedPhase 3NCT02404376

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Hospital Universitari Vall d'Hebron Research Instituten = 378Mar 2016 to Jun 2020

ST Elevation Acute Myocardial Infarction

Trial page ClinicalTrials.govUpdated 3 Nov 2020

Status unknownNot applicableNCT02577848

GLP-1 on Non-ST-Segment Elevation Myocardial Infarction

Chinese PLA General Hospitaln = 90Oct 2015 to est. Oct 2016

Myocardial Infarction

Trial page ClinicalTrials.govUpdated 19 Oct 2015

Status unknownNot applicableNCT02490176

Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

Chinese PLA General Hospitaln = 50Jul 2015 to est. Jul 2016

Heart Failure

Trial page ClinicalTrials.govUpdated 29 Feb 2016

Status unknownNot applicableNCT02001363

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Chen Wei Ren, MDn = 90Nov 2013 to est. Mar 2016

Acute Myocardial Infarction

Trial page ClinicalTrials.govUpdated 5 Feb 2016

CompletedPhase 4NCT00835848

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

Copenhagen University Hospital, Rigshospitaletn = 100Jan 2009 to May 2015

Myocardial Infarction

Trial page ClinicalTrials.govUpdated 5 May 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.